33 related articles for article (PubMed ID: 10663618)
1. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Kolitz JE; George SL; Benson DM; Maharry K; Marcucci G; Vij R; Powell BL; Allen SL; Deangelo DJ; Shea TC; Stock W; Bakan CE; Hars V; Hoke E; Bloomfield CD; Caligiuri MA; Larson RA;
Cancer; 2014 Apr; 120(7):1010-7. PubMed ID: 24382782
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg E; Tobiasson M; Greenberg P
Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.
Mao C; Fu XH; Yuan JQ; Yang ZY; Huang YF; Ye QL; Wu XY; Hu XF; Zhai ZM; Tang JL
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010248. PubMed ID: 26544114
[TBL] [Abstract][Full Text] [Related]
5. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Buyse M; Squifflet P; Lange BJ; Alonzo TA; Larson RA; Kolitz JE; George SL; Bloomfield CD; Castaigne S; Chevret S; Blaise D; Maraninchi D; Lucchesi KJ; Burzykowski T
Blood; 2011 Jun; 117(26):7007-13. PubMed ID: 21518931
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation: its role in cancer development and therapy.
Kurkjian C; Kummar S; Murgo AJ
Curr Probl Cancer; 2008; 32(5):187-235. PubMed ID: 18926282
[No Abstract] [Full Text] [Related]
7. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Ganser A; Heil G; Seipelt G; Hofmann W; Fischer JT; Langer W; Brockhaus W; Kolbe K; Ittel TH; Brack N; Fuhr HG; Knuth P; Höffken K; Bergmann L; Hoelzer D
Ann Hematol; 2000 Jan; 79(1):30-5. PubMed ID: 10663618
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]